Axsome Therapeutics (AXSM) News Today $103.53 +5.47 (+5.58%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Geode Capital Management LLC Boosts Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Geode Capital Management LLC boosted its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 0.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 912,538 shares of the company's stock after buying an aApril 14 at 4:03 AM | marketbeat.comAmerican Century Companies Inc. Invests $570,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)American Century Companies Inc. purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 6,731 shares of the company's stock, valuApril 14 at 3:11 AM | marketbeat.comTrexquant Investment LP Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Trexquant Investment LP purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,129 shares of the company's stock, valued at approxApril 13 at 4:46 AM | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Trading Down 6.9% - Should You Sell?Axsome Therapeutics (NASDAQ:AXSM) Shares Down 6.9% - What's Next?April 11 at 12:34 PM | marketbeat.comZacks Research Analysts Increase Earnings Estimates for AXSMAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Monday, April 7th. Zacks Research analyst R. Department now forecasts that the company will post earningApril 11 at 7:51 AM | marketbeat.comZacks Research Has Positive Outlook of AXSM FY2025 EarningsApril 11 at 1:53 AM | americanbankingnews.comZacks Research Issues Negative Outlook for AXSM EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Zacks Research reduced their Q1 2027 EPS estimates for Axsome Therapeutics in a note issued to investors on Monday, April 7th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.75 per share for thApril 10, 2025 | marketbeat.comSeeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to BuyApril 9, 2025 | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Now Covered by Jefferies Financial GroupJefferies Financial Group initiated coverage on shares of Axsome Therapeutics in a report on Monday. They set a "buy" rating and a $200.00 price objective on the stock.April 9, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Boosted by ADAR1 Capital Management LLCADAR1 Capital Management LLC raised its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 3,176.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 19,661 shares of the company's stock after purchasing an additional 19April 9, 2025 | marketbeat.comFranklin Resources Inc. Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Franklin Resources Inc. grew its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 13.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 182,290 shares of the company'April 9, 2025 | marketbeat.comQ1 EPS Forecast for Axsome Therapeutics Reduced by AnalystApril 9, 2025 | americanbankingnews.comKuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law FirmApril 8, 2025 | prnewswire.comAxsome Therapeutics to Report First Quarter 2025 Financial Results on May 5April 8, 2025 | globenewswire.comAtika Capital Management LLC Reduces Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Atika Capital Management LLC trimmed its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 61.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,000 shares of the company's stock after selApril 8, 2025 | marketbeat.comSchroder Investment Management Group Sells 34,158 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Schroder Investment Management Group decreased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 58.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,142 shares of tApril 8, 2025 | marketbeat.comJefferies Initiates Coverage of Axsome Therapeutics (AXSM) with Buy RecommendationApril 7, 2025 | msn.comWellington Management Group LLP Reduces Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Wellington Management Group LLP lowered its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 9.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 673,157 shares of the company's stock after selling 69,588 sApril 7, 2025 | marketbeat.comNorges Bank Acquires New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Norges Bank bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 403,026 shares of the company's stock, valued at approximately $34,100,000. NorgeApril 7, 2025 | marketbeat.comAxsome Therapeutics initiated with a Buy at JefferiesApril 7, 2025 | markets.businessinsider.comWilliam Blair Issues Pessimistic Forecast for AXSM EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - William Blair decreased their Q1 2025 earnings estimates for Axsome Therapeutics in a research note issued to investors on Tuesday, April 1st. William Blair analyst M. Minter now anticipates that the company will earn ($1.49) per share for tApril 6, 2025 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC WainwrightApril 6, 2025 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $200.00 price objective on shares of Axsome Therapeutics in a research note on Thursday.April 5, 2025 | marketbeat.comVanguard Group Inc. Sells 92,866 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Vanguard Group Inc. trimmed its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,902,479 shares of the company's stock after sellApril 5, 2025 | marketbeat.comWilliam Blair Expects Lower Earnings for Axsome TherapeuticsApril 5, 2025 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Sees Large Decline in Short InterestAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) was the target of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 4,910,000 shares, a drop of 14.0% from the February 28th total of 5,710,000 shares. Based on an average daily trading volume, of 938,000 shares, the days-to-cover ratio is currently 5.2 days. Currently, 13.0% of the company's shares are sold short.April 4, 2025 | marketbeat.comAxsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual MeetingApril 4, 2025 | globenewswire.comAxsome Therapeutics Becomes Oversold (AXSM)April 3, 2025 | nasdaq.comKLP Kapitalforvaltning AS Makes New $745,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)KLP Kapitalforvaltning AS acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,800 shares of the company's stock, valued at approximatApril 3, 2025 | marketbeat.comBofA says Phase 3 MDD trial miss has ‘no impact’ on Axsome price targetApril 2, 2025 | markets.businessinsider.comKuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law FirmApril 2, 2025 | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Shares Gap Down - Here's WhyAxsome Therapeutics (NASDAQ:AXSM) Shares Gap Down - What's Next?April 2, 2025 | marketbeat.comAxsome selloff on study miss should be ‘contained,’ says MizuhoApril 2, 2025 | markets.businessinsider.comNeedham & Company LLC Reiterates Buy Rating for Axsome Therapeutics (NASDAQ:AXSM)Needham & Company LLC reiterated a "buy" rating and set a $153.00 price target on shares of Axsome Therapeutics in a report on Tuesday.April 2, 2025 | marketbeat.comCorient Private Wealth LLC Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Corient Private Wealth LLC purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,829 shares of the company's stApril 2, 2025 | marketbeat.comAxsome shares fall after trial results disappointApril 1, 2025 | investing.comAxsome announces results from PARADIGM Phase 3 trial of solriamfetolApril 1, 2025 | markets.businessinsider.comAxsome to narrow focus of depression drug trial after limited success in initial runApril 1, 2025 | msn.comAxsome Therapeutics Dives Again On Its Second Big Drug Failure In A WeekApril 1, 2025 | msn.comAxsome slips as late-stage trial for depression therapy failsApril 1, 2025 | msn.comWhy Shares of Axsome Therapeutics Slumped TodayApril 1, 2025 | fool.comAxsome's depression treatment fails to meet main goal of late-stage studyApril 1, 2025 | reuters.comDnB Asset Management AS Has $6.24 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)DnB Asset Management AS grew its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1,100.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 73,770 shares of the company's stock after acquiApril 1, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by AnalystsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has been given a consensus recommendation of "Buy" by the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Fifteen research analysts have rated the stock with a buy rating. The average 1-year price target among brMarch 31, 2025 | marketbeat.comLoomis Sayles & Co. L P Sells 8,475 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Loomis Sayles & Co. L P trimmed its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 290,111 shares of the company's stock after sellMarch 30, 2025 | marketbeat.comMizuho Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $216.00Mizuho lifted their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a research note on Thursday.March 28, 2025 | marketbeat.comAxsome Therapeutics' ADHD Trial Achieves Primary, Key Secondary EndpointsMarch 27, 2025 | nasdaq.comPiper Sandler Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)March 27, 2025 | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4.9% - Here's What HappenedAxsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4.9% - Should You Sell?March 26, 2025 | marketbeat.com6,119 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Fox Run Management L.L.C.Fox Run Management L.L.C. acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 6,119 shares of the company's stock, valued at approximately $518,000. A number of othMarch 26, 2025 | marketbeat.com Remove Ads Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Media Mentions By Week AXSM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.830.86▲Average Medical News Sentiment AXSM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼2310▲AXSM Articles Average Week Remove Ads Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News TEVA News ITCI News GMAB News RDY News MRNA News ASND News QGEN News VTRS News ROIV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
